IQVIA(US:IQV)2026-02-05 15:02Financial Data and Key Metrics Changes - Full-year revenue growth of 6% and adjusted diluted earnings per share growth of 7% were reported, with free cash flow of $2.1 billion, representing about 100% of adjusted net income [5][21] - Fourth quarter revenue was $4,364 million, up 10.3% on a reported basis and 8.1% at constant currency, with adjusted EBITDA increasing by 5% year-over-year [21][23] - Full-year revenue reached $16.31 billion, up 5.9% reported and 4.8% at constant currency [22] Business Line Data and Key Metrics Changes - Technology Analytics Solutions revenue for Q4 was $1,821 million, up 9.8% reported and 7.1% at constant currency [21] - R&D Solutions revenue for Q4 was $2,333 million, up 9.1% reported and 8.2% at constant currency [21] - Contract Sales and Medical Solutions (CSMS) revenue for Q4 was $210 million, increased 18.6% reported and 15.3% at constant currency [21] Market Data and Key Metrics Changes - Net bookings for R&D Solutions totaled over $2.7 billion, growing 7% year-over-year, with a net book-to-bill ratio of 1.18 [10] - Backlog reached a record of $32.7 billion at the end of the quarter, growing 5.3% compared to the prior year [10][24] - Encouragingly, EVP funding was strong in Q4, reaching $33 billion according to Bioworld [11] Company Strategy and Development Direction - The company is simplifying its organization in 2026 to strengthen collaboration and enhance efficiency, aligning teams with the evolving operating model [15] - A strategic collaboration with Amazon Web Services was announced to accelerate digital transformation in the industry [11] - The company is focusing on AI-driven innovations and has deployed over 150 AI agents across various use cases [38] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the demand environment stabilizing, with improved customer trends and solid execution from sales teams [5][10] - The company anticipates revenue for 2026 to be between $17.15 billion and $17.35 billion, with adjusted EBITDA guidance of $3.975 billion to $4.025 billion [26][27] - Management emphasized that AI is viewed as an enabling technology rather than a threat, enhancing productivity and efficiency [41][62] Other Important Information - The company was recognized by Everest Group for AI leadership, being the only clinical research organization to receive the number one ranking for generative AI leadership in life sciences [12] - The last earnings call for CFO Ron Bruehlman was noted, who will transition to a senior advisory role [17][18] Q&A Session Summary Question: Concerns about AI disrupting established businesses - Management clarified that AI is seen as an opportunity rather than a challenge, emphasizing the proprietary data and domain expertise that differentiate the company [32][34][41] Question: Value and driver of the Cedar Gate acquisition - The acquisition is expected to enhance patient outcomes and provide analytics to payers, with projected revenue of about $140 million in 2025 [46][48] Question: Impact of AI on trial efficiency and demand for services - Management stated that AI will improve trial efficiency but does not foresee a reduction in the number of trials conducted by large pharma [70][72] Question: Margin trajectory and pass-through growth - Management indicated that pass-through growth was a significant driver of gross margin, with expectations for flat overall EBITDA margins in the upcoming year [76][84]